Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Adam Petrich, Brad Kahl, Howard Bailey, Kyungmann Kim, Nancy Turman, Mark Juckett

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

Original languageEnglish
Pages (from-to)57-61
Number of pages5
JournalLeukemia and Lymphoma
Issue number1
StatePublished - Jan 2008


  • Doxercalciferol
  • Myelodysplastic syndrome
  • Phase II study


Dive into the research topics of 'Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this